

Supplementary Table 3. Results of the final evaluations at the last follow-up

	All patients				Patients enrolled in the continuous trial			
	Active n=70	Sham n=67	Mean difference (95% CI)	p value	Active n=16	Sham n=15	Mean difference (95% CI)	p value
VAS decrease, mean (SD)	6.9±18.4	7.3±13.6	-0.4 (-6.7 to 5.8)	0.90	24.7±22.6	21.4±23.5	3.3 (-13.6 to 20.2)	0.69
VAS decrease rate, mean (SD), %	10.8±29.6	10.3±31.2	0.5 (-9.7 to 10.8)	0.92	40.9±36.8	32.5±36.3	8.4 (-18.4 to 35.3)	0.53
SF-MPQ2 decrease, mean (SD)	13.1±32.9	8.0±30.4	5.1 (-5.6 to 15.8)	0.35	37.6±31.5	15.1±33.8	22.5 (-1.5 to 46.5)	0.07
SF-MPQ2 decrease rate, mean (SD), %	20.5±48.2	13.6±46.7	6.8 (-9.2 to 22.9)	0.40	57.4±43.8	30.0±58.6	31.4 (-6.4 to 69.3)	0.10
BDI-II decrease, mean (SD) ^a	0.4±5.3	0.9±5.9	-0.6 (-2.4 to 1.3)	0.56	1.1±5.1	0.9±4.6	-0.2 (-3.4 to 3.8)	0.91
BDI-II decrease rate, mean (SD), % ^b	1.5±86.9	-0.2±113.1	1.6 (-35.4 to 38.7)	0.93	15.9±73.8	-10.7±169.9	26.7 (-76.6 to 129.9)	0.60
MMSE increase, mean (SD)	0.1±1.7	0.1±1.8	-0.1 (-0.7 to 0.5)	0.80	-0.4±1.8	0.1±1.6	-0.6 (-1.8 to 0.7)	0.36
MMSE increase rate, mean (SD), %	0.3±6.0	0.6±6.6	-0.3 (-2.5 to 1.8)	0.78	-1.4±6.1	0.6±5.6	-2.0 (-6.3 to 2.3)	0.36

Abbreviations: VAS, visual analogue scale; SF-MPQ2, short-form McGill pain questionnaire 2; BDI-II, Beck Depression Inventory second version; MMSE, Mini mental state examination.

^a Analysis was performed in 69 (active) and 67 (sham) patients for the all patients.

^b Analysis was performed in 56 (active) and 62 (sham) patients for the all patients, and in 14 (active) and 12 (sham) patients for the patients enrolled in the continuous trial.